All News

Article

IV Secukinumab for AxSpa

Eric Dein, MD

The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis. Data for this new approval will be presented at ACR Convergence on November 14th by Dr. Atul Deodhar.

Eric Dein Tweet
A#2547 #ACR23 @RheumNow Diff 2 Treat (D2T) AxSpa D2T: fail 2+ b/tsDMARDs w 2 MoA Very D2T: failure of Rx in less than 2 yrs 28% D2T, 3.8% Very D2T (Compare to 7-10% D2TRA) More likely: peripheral, uveitis, higher BASDAI, FM Very D2T also w IBD, higher CRP, longer dis duration https://t.co/HcIXnDRrIq
Robert B Chao, MD Tweet
Another infusion option for axSpA! INVIGORATE-1: Phase 3 RCT of IV Secukinumab in axSpA Efficacious - ASAS40 response sustained thru 52 weeks Safety profile similar to subq version @RheumNow #ACR23 Abs#2545 https://t.co/biC8p3p6dl
Janet Pope Tweet
Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR
Dr. Rachel Tate Tweet
Super interesting SpA phenotypical type world map. #ACR23 Abs #2195 continues to prove how heterogenous this disease is and the need for additional therapeutic agents for improved patient outcomes. https://t.co/hpKY7usUUb @rheumnow https://t.co/xJ1bx6wOC0
sheila Tweet
In this older grp of pts w/ chronic LBP, significant overlaps of deg & inflamm features on spinal imaging of DC, DISH & axSpA pts were seen Also, +comorbids: HTN in DC; DM in DISH; smoking in axSpA THM? DC & DISH are also axSpA mimics #ACR23 ABST1862 @Rheumnow @rheumarhyme https://t.co/uNIwRchF1g
sheila Tweet
Will postpartum BME ⏩axSpA-like structural lesions? Study by Varkas et al show there was no significant dev't of axSpA-like lesions on MRI in postpartum women 5 yrs after delivery. Postpartum BME likely sec to transient mech stress-induced SI BME #ACR23 ABST1892 @RheumNow https://t.co/KJ3DngmkbI
Robert B Chao, MD Tweet
Always refreshing to hear from another specialist's point of view Cardiologist @Bweber04 on CVD and rheumatologic diseases Increased risk of death, MI and HF exacerbation in our pt population Increased all cause mortality @RheumNow #ACR23 https://t.co/yOkPOmxU4N
Eric Dein Tweet
Later today at #ACR23 at 4pm See Ab#2545 on IV secukinumab for AxSpA Read about it now on @RheumNow: https://t.co/s9IinpVxgR
Mike Putman Tweet
EBRheum
Amazing & thoughtful poster re:protocol violates in TICOSPA trial 51.2% of pts violated T2T protocol at least once... but did not impact primary outcome Good baseline for future "strategy" style pragmatic trials @RheumNow #ACR23 #ACRBest Abstr2201 https://t.co/FhctgFNdNP
Eric Dein Tweet
CV Events in AS by Rx A#L11 @RheumNow #ACR23 43K pts from Korean data Rates of incident MI or CV: 18.7 per 10,000 py in non-bDMARD pt 8.9 in TNF 12.9 in IL-17 TNFi reduced risk of CVD HR 0.7, not signif for IL-17 Supports idea of TNFi giving a cardioprotective effect? #ACRBest https://t.co/SvVVDSU23z
Dr. Rachel Tate Tweet
Be a SpA (and PsA) Sleuth! My article is your call to arms for better understanding and discovery of IBD in our inflammatory back pain patients. Consider fecal calprotectin AND robust ROS as your magnifying glass! #ACR23 @rheumnow https://t.co/OnQDEWgIWM
Dr. Rachel Tate Tweet
From patient to research/clinical rheumatologist and SpA advocate. Check out my #ACR23 interview with Dr. Hillary Norton. @DrHillaryNorton @RheumNow https://t.co/SeZeqb8wid
Dr. Rachel Tate Tweet
Dr. Alexis Ogdie updates me on her #ACR23 must knows for SpA/PsA patients @RheumNow https://t.co/hFLzLtmcSl
Eric Dein Tweet
Went into more depth on this great topic of IBD in SpA on @RheumNow #ACR23 Should we be screening SpA patients with fecal calprotectin to look for undiagnosed SpA? https://t.co/TmXhm2MEfO https://t.co/SWJSqF5pkW
Janet Pope Tweet
#irAE Baseline immune suppression does NOT protect against worsening synovitis flares when using check point inhibitors in Pts with established #inflammatory #arthritis #ACRbest #ACR23 @ACRheum @RheumNow abst1075 Data from #CanRIO database https://t.co/lOCf8Tbgta
Dr. Rachel Tate Tweet
#ACR23 Abs #2199 large RL study: SEC retention rates after 4 yrs approx. 50% in axSpA and PsA pts. Bio-naïve pts had higher retention, remission & response rates than pts with prior b/tsDMARD exposure, particularly in axSpA. https://t.co/Eq5BwILK3D @rheumnow https://t.co/slho6yAwtQ
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×